Combination therapy with the autophagy inhibitor 3-MA and trastuzumab showed a better effect in HER2-positive breast cancer cells, and inhibition of the autophagy-related factors ATG5, ATG7, and Beclin1 reduced resistance to tamoxifen in ER-positive breast cancer [33,34]. This evidence concerns the gene ATG5 and breast carcinoma.